MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net



| Suggested Formula | Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 mL] Tablets) | FIN | F 005 473v4 |
|---|---|---|---|

## SUGGESTED FORMULATION

| Ingredient Listing | Qty. | Unit | NDC # | Supplier | Lot Number | Expiry Date |
|---|---|---|---|---|---|---|
| Caffeine (Anhydrous), USP | 9.600 | g | | | | |
| Scopolamine Hydrobromide, USP | 0.050 | g | | | | |
| Mango Flavor (Powder) | 0.75 | g | | | | |
| Raspberry Flavor (Powder) | 0.40 | g | | | | |
| Vanillin Flavor (Powder) | 0.50 | g | | | | |
| Stevia Powder (Stevioside) | 0.20 | g | | | | |
| Bitterness Reducing Agent (NF01) Natural (Powder) | 0.75 | g | | | | |
| Medi-RDT Base | TBD | | | | | |

**Note: The amount of Scopolamine Hydrobromide to weigh is very small, therefore, it is recommended to use a 4 decimal analytical balance.

## SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

***Light sensitive*** *(protect from light whenever possible):* *Scopolamine Hydrobromide*

***Hygroscopic*** *(protect from moisture whenever possible):* *Medi-RDT Base, Stevia Powder*

Suggested Preparatory Guidelines

■ Non-Sterile Preparation ☐ Sterile Preparation

Processing Error / Testing Considerations: To account for processing errors and considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

**IMPORTANT**: This procedure involves heating the tablet mold at temperatures reaching 110°C. Ensure that your molds are able to withstand this temperature.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net



| Suggested Formula | Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 mL] Tablets) | FIN | F 005 473v4 |
|---|---|---|---|

## SUGGESTED PREPARATION (for 96 Tablets)

Weigh and / or measure the following ingredients when appropriate:

| Ingredient Listing | Qty. | Unit | Multiplication factor (*): ____ | Processing Error | Qty. to measure |
|---|---|---|---|---|---|
| Caffeine (Anhydrous), USP | 9.600 | g | | | |
| Scopolamine Hydrobromide, USP § | 0.050 | g | | | |
| Mango Flavor (Powder) | 0.75 | g | | | |
| Raspberry Flavor (Powder) | 0.40 | g | | | |
| Vanillin Flavor (Powder) | 0.50 | g | | | |
| Stevia Powder (Stevioside) § | 0.20 | g | | | |
| Bitterness Reducing Agent (NF01) Natural (Powder) | 0.75 | g | | | |
| Medi-RDT Base § | TBD | | | | |

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

| Preparatory Instruction | |
|---|---|
| 1. | **Mold calibration:**<br><br>Determine the required quantity of Medi-RDT Base for 96 tablets based on the actual size of the tablet mold being used. Refer to the Appendix for details. |

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net



| Suggested Formula | Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 mL] Tablets) | FIN | F 005 473v4 |
|---|---|---|---|

2. **Powder preparation:**

A. Pass the Medi-RDT Base through a 40 or 50 mesh sieve and weigh the required quantity (amount calculated in Appendix Step 6Aiii).

B. By geometric addition, combine and triturate the following ingredients together to form a homogeneous powder blend:

-Caffeine (Anhydrous)
-Scopolamine Hydrobromide
-Mango Flavor (Powder)
-Raspberry Flavor (Powder)
-Vanillin Flavor (Powder)
-Stevia Powder (Stevioside)
-Bitterness Reducing Agent (NF01) Natural (Powder)

C. By geometric addition, combine and mix (DO NOT TRITURATE) the following ingredients together to form a homogeneous powder blend:

-Sieved Medi-RDT Base (Step 2A)
-Homogeneous powder blend (Step 2B)

Note: Do not use excessive force as Medi-RDT Base should not be triturated.

D. Prior to filling the tablet mold cavities, pass the homogeneous powder blend (Step 2C) through a 40 or 50 mesh sieve to improve flow properties and obtain content uniformity.

3. **Mold filling and heating:**

A. Fill the 96 tablet mold cavities by tapping and pressing the sieved homogeneous powder blend (Step 2D) into the cavities using the upper part of the mold. Repeat at least three times to ensure the cavities are completely filled. If necessary, add additional powder blend.

B. Gently heat the powder blend to 105°C – 110°C for 10 – 15 minutes. Do not overheat.

Specifications: Heat by placing the filled mold (base cavity plate only) in an appropriate oven, preheated to 105°C – 110°C.

End Result: Homogeneous solid dispersion.

| Suggested Formula | Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 mL] Tablets) | FIN | F 005 473v4 |
|---|---|---|---|

| | |
|---|---|
| 4. | **Cooling:**<br><br>A. Carefully remove the tablet mold from the heated oven, using a hot hand protector.<br><br>B. Immediately remove the tablets by flipping over the mold onto a piece of wax or ointment paper and gently tapping the mold with a mini mallet.<br><br>Note: Hold the tablet mold in place while tapping to avoid shaking and breaking the tablets.<br><br>C. Allow the tablets to cool for an additional 30 minutes at controlled temperature and relative humidity. |
| 5. | **Validation technique:**<br><br>A. Weigh 20 tablets separately.<br><br>B. The final weight of each tablet from Step 5A (not including the weight of the tablet mold) should be between 90 and 110% of the theoretically calculated weight (Appendix, Step 5B), in accordance to USP guidelines. |
| 6. | **Product transfer:**<br><br>Transfer the final product into the specified dispensing container (see “Packaging Requirements”). |

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net



| Suggested Formula | Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 mL] Tablets) | FIN | F 005 473v4 |
|---|---|---|---|

## SUGGESTED PRESENTATION

| | | | | | |
|---|---|---|---|---|---|
| Estimated Beyond-Use Date | | 6 months, as per USP*. | Packaging Requirements | | Manually put into light-resistant Medi-RDT blisters and cold seal with foil labels. |
| Auxiliary Labels | 1 | Use as directed. Do not exceed prescribed dose. | | 6 | May impair mental and or physical ability. Use care when operating a car or machinery. |
| | 2 | Keep out of reach of children. | | 7 | Keep at room temperature (20°C – 23°C). |
| | 3 | Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants. | | 8 | Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use. |
| | 4 | Protect from light. | | 9 | Keep in a dry place. |
| | 5 | Discard container after use. | | 10 | May produce psychological and/or physical dependence. |
| Pharmacist Instructions | Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. | | | | |
| Patient Instructions | Contact your pharmacist in the event of adverse reactions. | | | | |

*** The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.**

| | | | |
|---|---|---|---|
| Suggested Formula | Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 mL] Tablets) | FIN | F 005 473v4 |

## REFERENCES


1. Tablets. In: Allen, LV, Jr. *The Art, Science and Technology of Pharmaceutical Compounding Third Edition.* American Pharmaceutical Association; 2008: 145.
2. Caffeine. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 36th Edition.* London, England: The Pharmaceutical Press; 2009: 1116.
3. Hyoscine Hydrobromide. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 36th Edition.* London, England: The Pharmaceutical Press; 2009: 1734.
4. Caffeine (Monograph). In: O'Neil MJ. *The Merck Index 14th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #1636.
5. Scopolamine (Monograph). In: O'Neil MJ. *The Merck Index 14th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #8406.
6. Caffeine. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 4th Edition.* American Pharmaceutical Association; 2009: 82.
7. Caffeine (Monograph). *United States Pharmacopeia XXXVI / National Formulary 31.* Rockville, MD. US Pharmacopeial Convention, Inc. 2013: 2731.
8. Scopolamine Hydrobromide (Monograph). *United States Pharmacopeia XXXVI / National Formulary 31*. Rockville, MD. US Pharmacopeial Convention, Inc. 2013: 5113.
9. USP <795>. *United States Pharmacopeia XXXVI / National Formulary 31.* Rockville, MD. US Pharmacopeial Convention, Inc. 2013: 355.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net



| Appendix | Tablet mold calibration | | |
|---|---|---|---|

## SUGGESTED CALCULATION

Preparatory Instruction

1. **API weighing:**

A. Pass the Medi-RDT Base through a 40 or 50 mesh sieve.

B. Weigh and / or measure the following ingredients:

| Ingredient | Quantity |
|---|---|
| Caffeine (Anhydrous), USP | 1.000 g |
| Medi-RDT Base | 8.08 g |

**Notes:** Measure the exact amount specified. Do not consider processing error for calibration step.
Data within this calibration table are based on a 0.93 mL mold size.

2. **Powder preparation:**

A. Triturate the Caffeine (Anhydrous) to form a fine, homogeneous powder.

B. By geometric addition, combine and mix (DO NOT TRITURATE) the following ingredients together to form a homogeneous powder blend:

-Medi-RDT Base
-Homogeneous powder blend (Step 2A)

Note: Do not use excessive force as Medi-RDT Base should not be triturated.

C. Prior to filling the tablet mold cavities, pass the homogeneous powder blend (Step 2B) through a 40 or 50 mesh sieve to improve flow properties and obtain content uniformity.

3. **Mold filling and heating:**

A. Fill 5 tablet mold cavities by tapping and pressing the sieved homogeneous powder blend (Step 2C) into the cavities using the upper part of the mold. Repeat at least three times to ensure the cavities are completely filled. If necessary, add additional Medi-RDT Base.

B. Gently heat the powder blend to 105°C – 110°C for 10 – 15 minutes. Do not overheat.

Specifications: Heat by placing the filled mold (base cavity plate only) in an appropriate oven, preheated to 105°C – 110°C.

End Result: Homogeneous solid dispersion.

| Appendix | Tablet mold calibration | | |
|---|---|---|---|

4. **Cooling:**

A. Carefully remove the tablet mold from the heated oven, using a hot hand protector.

B. Immediately remove the tablets by flipping over the mold onto a piece of wax or ointment paper and gently tapping the mold with a mini mallet.

Note: Hold the tablet mold in place while tapping to avoid shaking and breaking the tablets.

C. Allow the tablets to cool for an additional 30 minutes at controlled temperature and relative humidity.

5. **Calculate the average tablet weight:**

A. Weigh the five tablets and record the total weight here (not including the weight of the empty tablet mold): _____ g

B. Calculate the average tablet weight:

| | |
|---|---|
| Combined weight of the tablets (from Step 5A) | _____ g |
| DIVIDED BY | |
| Number of Tablets | 5 |
| EQUALS | |
| **Average (theoretical) tablet weight*** | _____ **g** |

***Note:** The weight of the Rapid-Dissolving Tablets is mainly affected by factors such as compression force, flow properties of the powder mixture (flow properties will vary depending on the Active Pharmaceutical Ingredient(s) and excipients in the formulation) and particle size distribution. The mixture must be sieved prior to filling.

The expected average weight of RDT's are as follows (data based on various experiments/troubleshooting completed in the past):

750mg ± 30mg (720mg - 780mg)
200mg ± 10mg (190mg - 210mg)
150mg ± 7.5mg (142.5mg - 157.5mg)
75mg ± 5mg (70mg - 80mg)

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net



| Appendix | Tablet mold calibration | | |
|---|---|---|---|

6. **Ingredient calculation:**

A. Calculate the quantity of excipient blend required for 96 tablets:

| | |
|---|---|
| Average tablet weight (from Step 5B) | _____ g |
| MINUS | |
| Total quantity (in g) of Caffeine, Scopolamine Hydrobromide and Flavors per tablet | 0.128 g |
| EQUALS | |
| **i. Quantity of Medi-RDT Base required per tablet** | _____ g |
| MULTIPLY BY | |
| Number of tablets required | 96 |
| EQUALS | |
| **ii. Total quantity of Medi-RDT Base required for 96 tablets** | _____ **g** |
| MULTIPLED BY | |
| Processing error adjustments (5 to 9%) | 1.05 to 1.09 |
| EQUALS | |
| **iii. Total quantity of Medi-RDT Base required *plus* processing error adjustments** | _____ g |